ClinicalTrials.gg
Active, not recruitingNCT06064071Updated Nov 2, 2026

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

An interventional study of Nordlys SWT IPL and Meibomian Gland Expression (MGX) in Meibomian Gland Dysfunction and Dry Eye Disease, sponsored by Candela Corporation. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Candela Corporation · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Meibomian Gland Dysfunction with a site in United States — 7 open to participants now, 11 under way, none of them phase 3. Meibomian Gland Dysfunction · United States.

Planned enrollment
14th of 62
100 · median 44
Started
2023
with 5 others
No phase
43 of 64
4 open now
Primary completion
2027-09
later than 10 of 10 live
Registered
52nd of 64
by date

Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, this one is the 14th largest by planned enrollment of the 62 interventional ones that give a count, is one of 6 that started in 2023, is one of 43 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 52nd registered.

Meibomian Gland Dysfunction

173 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.

Browse Meibomian Gland Dysfunction studies →

Open to participants now

7 of the 64 studies in Meibomian Gland Dysfunction with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Meibomian Gland Dysfunction with a site in United States, or all of them as a file.
02

Study summary

Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).

Read the detailed description

Subjects will be randomized 1:1 to an experimental study group and a sham comparator (control) group.

Subjects in the experimental group will receive four (4) IPL treatments and meibomian gland expression (MGX) at 2-week intervals. IPL pulses will be administered on the skin of the malar region and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes. Subjects in the control group will receive the same treatment (IPL followed by MGX), except that the IPL administration will be performed with the device off (sham treatment). Follow-up visits will occur at 1 month and 3 months after the final treatment session. At the follow-up, the changes in the outcome measures will be evaluated and compared between the two groups.

03

Conditions studied

  • Meibomian Gland Dysfunction
  • Dry Eye Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female and male subjects between 18 to 75 years of age with Fitzpatrick Skin Type I - VI.
  • Able and willing to comply with the treatment/follow-up schedule and requirements comply with all study (protocol) requirements.
  • Willingness to provide signed, to participate in the study
  • Willing to have photographs and images taken of the treated areas to be used in evaluations, publications, presentations, and marketing materials
  • Has Tear Breakup Time (TBUT) ≤ 7 seconds at screening/baseline
  • Has Meibomian gland secretion score (MGS) ≤ 12 at screening/ baseline
  • Has at least 5 non-atrophied meibomian glands and at least 50% of working meibomian glands in the lower eyelid at screening/ baseline
  • Symptoms self-assessed using the OSDI questionnaire ≥ 23 at screening/ baseline

Exclusion criteria

Exclusion Criteria:

  • Contact lens wear within the month prior to screening
  • Unwilling to discontinue use of contact lenses for the duration of the study
  • Ocular surgery or eyelid surgery, within 6 months prior to screening
  • Neuro-paralysis in the planned treatment area, within 6 months prior to screening
  • Other uncontrolled eye disorders affecting the ocular surface, for example active allergies
  • Current use of punctal plugs
  • Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
  • Uncontrolled infections or uncontrolled diseases
  • Subjects with ocular infections, within 6 months prior to screening
  • Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm, including: Herpes simplex 1 \& 2, Systemic Lupus erythematosus, and porphyria unless treated following a prophylactic regimen per principal investigator discretion.
  • Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
  • Over exposure to sun, within 4 weeks prior to screening
  • Use of prescription eye drops for dry eye, within 7 days prior to screening, excluding artificial tears and glaucoma drops
  • Radiation therapy to the head or neck, within 12 months prior to screening
  • Planned radiation therapy, within 8 weeks after the last treatment session
  • Treatment with chemotherapeutic agent, within 8 weeks prior to screening
  • Planned chemotherapy, within 8 weeks after the last treatment session
  • New topical treatments within the area to be treated, or oral therapies, within 3 months prior to screening- except over-the-counter acetaminophen-based analgesics for pain management, new oral omega 3 fatty acid supplements and topical artificial tears
  • Change in dosage of any systemic medication, within 3 months prior to screening
  • Anticipated relocation or extensive travel outside of the local study area preventing compliance with follow-up over the study period
  • Legally blind in either eye
  • History of migraines, seizures or epilepsy
  • Facial IPL treatment within 12 months prior to screening
  • Any thermal treatment of the eyelids, including Lipiflow, within 6 months prior to screening
  • Expression of the meibomian glands, within 6 months prior to screening
  • In either eye, moderate to severe inflammation of the conjunctiva, including: allergic, vernal or giant papillary conjunctivitis or severe inflammation of the eyelid, including: blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis
  • Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy)
  • Eyelid abnormalities that affect lid function in either eye, including: entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, and severe ptosis
  • Any systemic condition that may cause dry eye disease, including: Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, and Sjögren's syndrome
  • Unwilling or unable to abstain from the use of medications known to cause dryness (e.g., isotretinoin, antihistamines) throughout the study duration. Subjects must discontinue these medications for at least 1 month prior to the baseline visit.
  • Any condition revealed whereby the investigator deems the subject inappropriate for this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental: Nordlys SWT IPL

    Subjects will receive up to four study Nordlys SWT IPL treatments and MGX

    Device: Nordlys SWT IPL · Procedure: Meibomian Gland Expression (MGX)

  • Sham comparator
    Control Group: Sham Treatment

    Subjects will receive up to four sham study Nordlys SWT IPL treatments (device turned off) and MGX

    Procedure: Meibomian Gland Expression (MGX) · Device: Sham Nordlys SWT IPL

Interventions

  • DeviceNordlys SWT IPL

    Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators

  • ProcedureMeibomian Gland Expression (MGX)

    Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction

  • DeviceSham Nordlys SWT IPL

    Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off

06

What researchers measure

Primary outcomes

  1. Improvement of Tear Breakup Time (TBUT) from baseline to 4-week follow-up

    The difference in the change of TBUT from Baseline to Follow-Up, between eyes in the study group and eyes in the control group. TBUT is measured in seconds. Improvement is defined as a positive change of TBUT from Baseline to Follow Up. Measurement of TBUT will be implemented using fluorescein ophthalmic strips. Three successive readings will be taken and averaged to a single value.

    Time frame: Baseline, 4-Week Follow Up (Week 10)

Secondary outcomes

  1. Difference in change of self-assessed symptoms with the Ocular Surface Disease Index (OSDI) questionnaire, from baseline to follow-up.

    The difference in the change of OSDI from baseline to FU, between subjects in the study group and subjects in the control group. The minimal number is 0 and the maximal number is 100. Higher scores mean worse outcome. A score of 0-12 is considered normal. A score of 13-22 is consistent with mild dry eye. A score of 23 to 32 is consistent with moderate dry eye. A score from 33 to 100 is consistent with severe dry eye. The improvement of OSDI is defined as a negative change of OSDI from BL to FU.

    Time frame: Baseline, 1 Month Follow Up at Week 10, and 3 Month Follow Up at Week 18

  2. The difference in change of self-assessed symptoms of eye dryness via Eye Dryness Score (EDS) via visual analog scale (VAS), from baseline to follow-up

    A qualitative test to visualize the production of sweat to the affected body area and assist in determining the area requiring treatment. Values will be collected separately for each eye. Correlation between eyes was removed by statistical methods. Scores were 0 (minimum) to 100 (maximum). Higher scores = worse outcome. The improvement of EDS is defined as a negative change of EDS from baseline to follow-up.

    Time frame: Baseline, 1 Month Follow Up at Week 10, and 3 Month Follow Up at Week 18

07

Study locations

3 sites
  • Center for Excellence in Eye Care
    Miami, Florida 33176, United States
  • Candela Institute of Excellence
    Marlborough, Massachusetts 01752, United States
  • Av. Del Libertador 662, Piso 17, Dept. 42
    Buenos Aires, Argentina
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 23 industry-sponsored interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 48 months is above that.

Counting every sponsor, half of 75 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2025 → Sep 2027 and completion Sep 2025 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2023
First posted
Oct 3, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Sep 2027was Sep 2025
CompletionEst.
Sep 2027was Sep 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2025→Sep 2027
Nov 2, 2026
Study completion
Sep 2025→Sep 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Sep 2025→Sep 2027
    Study completion Sep 2025→Sep 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06064071
Responsible party
Sponsor
First posted
Oct 3, 2023
Start date
Sep 18, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion